Patrick W. Cobb, MD - Billings, MT ...

Dr. Patrick Cobb, MD

Claim this profile

St. Vincent Frontier Cancer Center

Studies Breast Cancer
Studies Non-Small Cell Lung Cancer
24 reported clinical trials
48 drugs studied

Area of expertise

1Breast Cancer
Patrick Cobb, MD has run 4 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
BRCA positive
2Non-Small Cell Lung Cancer
Patrick Cobb, MD has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
BRAF negative

Affiliated Hospitals

Image of trial facility.
St Vincent Frontier Cancer Center
Image of trial facility.
Saint Vincent Frontier Cancer Center

Clinical Trials Patrick Cobb, MD is currently running

Image of trial facility.

Atezolizumab + Chemotherapy

for Neuroendocrine Carcinoma

This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting1 award Phase 2 & 310 criteria
Image of trial facility.

Nivolumab + Standard Treatment

for Stomach and Esophageal Cancer

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria

More about Patrick Cobb, MD

Clinical Trial Related6 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Patrick Cobb, MD has experience with
  • Carboplatin
  • Pembrolizumab
  • Placebo
  • Pemetrexed
  • Rituximab
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Patrick Cobb, MD specialize in?
Is Patrick Cobb, MD currently recruiting for clinical trials?
Are there any treatments that Patrick Cobb, MD has studied deeply?
What is the best way to schedule an appointment with Patrick Cobb, MD?
What is the office address of Patrick Cobb, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security